Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F. Xing Y, et al. Among authors: doyle la. Breast Cancer Res. 2019 Jul 5;21(1):78. doi: 10.1186/s13058-019-1154-8. Breast Cancer Res. 2019. PMID: 31277699 Free PMC article. Clinical Trial.
SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.
Gonzalez-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F. Gonzalez-Angulo AM, et al. Among authors: doyle la. J Natl Cancer Inst. 2015 Feb 16;107(3):dju493. doi: 10.1093/jnci/dju493. Print 2015 Mar. J Natl Cancer Inst. 2015. PMID: 25688104 Free PMC article. Clinical Trial.
Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035).
Lee EK, Tan-Wasielewski Z, Aghajanian C, Coleman RL, Curtis J, Hirsch MS, Matulonis UA, Cantley LC, Mills GB, Doyle LA, Liu JF. Lee EK, et al. Among authors: doyle la. Gynecol Oncol Rep. 2020 Feb 3;32:100546. doi: 10.1016/j.gore.2020.100546. eCollection 2020 May. Gynecol Oncol Rep. 2020. PMID: 32083163 Free PMC article.
Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.
Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK, Rohren E, Ng C, Chandhasin C, LoRusso P. Naing A, et al. Among authors: doyle la. Clin Cancer Res. 2011 Sep 15;17(18):6052-60. doi: 10.1158/1078-0432.CCR-10-2979. Epub 2011 Jul 12. Clin Cancer Res. 2011. PMID: 21750201 Free PMC article. Clinical Trial.
A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.
Jonasch E, Hasanov E, Corn PG, Moss T, Shaw KR, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do KA, Altamirano PF, Zurita AJ, Doyle LA, Lara PN Jr, Tannir NM. Jonasch E, et al. Among authors: doyle la. Ann Oncol. 2017 Apr 1;28(4):804-808. doi: 10.1093/annonc/mdw676. Ann Oncol. 2017. PMID: 28049139 Free PMC article. Clinical Trial.
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.
Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R. Naing A, et al. Among authors: doyle la. Clin Cancer Res. 2012 May 1;18(9):2625-31. doi: 10.1158/1078-0432.CCR-12-0061. Epub 2012 Mar 31. Clin Cancer Res. 2012. PMID: 22465830 Free PMC article. Clinical Trial.
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.
Ma CX, Suman V, Goetz MP, Northfelt D, Burkard ME, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tevaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, Hieken T, Barnell EK, Skidmore ZL, Feng YY, Krysiak K, Hoog J, Guo Z, Nehring L, Wisinski KB, Mardis E, Hagemann IS, Vij K, Sanati S, Al-Kateb H, Griffith OL, Griffith M, Doyle L, Erlichman C, Ellis MJ. Ma CX, et al. Clin Cancer Res. 2017 Nov 15;23(22):6823-6832. doi: 10.1158/1078-0432.CCR-17-1260. Epub 2017 Sep 5. Clin Cancer Res. 2017. PMID: 28874413 Free PMC article. Clinical Trial.
The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab.
Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S, Hong DS, Chen HX, Doyle LA, Kurzrock R, Naing A. Busaidy NL, et al. Among authors: doyle la. Oncologist. 2015 Jul;20(7):737-41. doi: 10.1634/theoncologist.2015-0065. Epub 2015 Jun 8. Oncologist. 2015. PMID: 26054632 Free PMC article. Clinical Trial.
220 results